Capture Vascular, Inc. (Capture), a Telluride Medical Partners company, announced today that it has received CE (Conformité Européenne) marking for its proprietary MegaVac Mechanical Thrombectomy System.
“The CE mark is a critical milestone for Capture; the team has been working on its issuance since mid-2017,” stated Eric Wells, CEO of Capture. “We can now launch our sales efforts in Europe, a market that has expressed great interest in Capture’s technology,” stated Wells.
Capture is currently in early discussions with a number of European distribution partners, has a few agreements in place, and is working diligently to finalize additional agreements now that the CE mark has been issued.
“We are confident that Vascular Surgeons, Interventional Cardiologists, and Interventional Radiologists throughout Europe will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive peripheral treatments,” stated Wells.
Capture’s proprietary technology includes key features such as centering and securing the occlusion funnel tip position within the vessel and being able to pass other lesion disruptive devices through its lumen.
Founded in 2013, Capture’s proprietary technology includes the MegaVac Catheter with SafeSeal Technology and the ThromboWire Clot Retractor, which makes up the MegaVac Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. For more information about Capture Vascular and its technology please visit www.capturevascular.com.